The controlled release drug delivery industry focuses on developing systems that manage the release of therapeutic agents over time. This approach enhances the effectiveness of existing medications, providing better patient adherence and outcomes. Companies in this sector range from startups to larger firms, specializing in various delivery mechanisms such as injectables, oral forms, and transdermal patches. The industry is evolving rapidly, driven by technological advancements and a growing emphasis on personalized medicine. Current trends suggest an increasing need for tailored therapies that transform complex diseases into manageable conditions, promising significant growth for innovators in this space.

The listed companies showcase a spectrum of expertise, ranging in size from small startups to large organizations. Located across various countries—including Greece, the Netherlands, and the USA—these firms have been established mainly since the early 2000s. Their specializations cover a wide range of controlled release technologies, addressing needs in oncology, pain management, and chronic disease care. With innovative product pipelines and dedicated R&D investments, these companies are poised to influence improvements in drug delivery practices significantly.

Read on for insights into top controlled release drug delivery companies.

Top 23 Controlled Release Drug Delivery Companies

1. Pharmathen

• Website: pharmathen.com
• Ownership type: Private Equity
• Headquarters: Marousi, North Athens Regional Unit, Greece
• Employee distribution: Greece 96%, Other 4%
• Latest funding: $1.9B, July 2021
• Founded year: 1969
• Headcount: 1001-5000
• LinkedIn: pharmathen

Pharmathen, founded in 1969 and based in Marousi, Greece, is a pharmaceutical company that specializes in innovative drug delivery technologies. With a workforce of over 1,000 employees, Pharmathen has established itself as a significant player in the pharmaceutical sector, focusing on the development of advanced pharmaceutical products. The company offers a range of solutions, including long-acting injectables, sustained release formulations, and preservative-free ophthalmic products. Pharmathen operates globally, serving pharmaceutical companies and healthcare providers in more than 90 countries. Their commitment to research and development is underscored by a pipeline of over 40 products and an annual investment of €35 million in R&D. Pharmathen's manufacturing facilities are approved by both the US FDA and EU authorities, ensuring high-quality production standards. The company aims to improve patient compliance and healthcare outcomes through its innovative technologies and product offerings.

2. InnoCore Pharmaceuticals

• Website: innocorepharma.com
• Ownership type: Private
• Headquarters: Groningen, Groningen, Netherlands
• Employee distribution: Netherlands 100%
• Latest funding: Other (Grant), January 2021
• Founded year: 2003
• Headcount: 11-50
• LinkedIn: innocore-technologies

InnoCore Pharmaceuticals, founded in 2003 and based in Groningen, Netherlands, is a pharmaceutical company that focuses on drug delivery technologies. The firm specializes in developing injectable sustained release products aimed at treating chronic diseases. Utilizing proprietary platforms like SynBiosys® and LiQuidPolymer™, InnoCore creates biodegradable sustained release formulations that enhance patient compliance and drug efficacy. Their technology allows for the controlled release of therapeutic compounds, including small molecules, peptides, and proteins, over extended periods. InnoCore has established partnerships with various biomedical and pharmaceutical companies, demonstrating their active involvement in the industry. Notably, their collaboration with Merck KGaA aims to develop long-acting injectable formulations, showcasing their commitment to addressing formulation challenges in drug delivery. The company operates with a dedicated team of professionals and maintains a focus on research and development, ensuring they remain relevant in the evolving pharmaceutical landscape.

3. Nanomi

• Website: nanomi.com
• Ownership type: Private
• Headquarters: Oldenzaal, Overijssel, Netherlands
• Employee distribution: Netherlands 100%
• Founded year: 2004
• Headcount: 11-50
• LinkedIn: nanomi

Nanomi is a pharmaceutical company based in Oldenzaal, Netherlands, founded in 2004. The company specializes in drug delivery systems, particularly focusing on long-acting release injectable medicines. Utilizing its proprietary Microsieve technology, Nanomi produces well-defined microspheres and nanoparticles that cater to the needs of pharmaceutical companies and healthcare providers. Their products are designed to enhance patient compliance and improve therapeutic outcomes by ensuring controlled and reproducible medication delivery. Nanomi operates under stringent quality standards, employing aseptic GMP processes at full commercial scale. As a subsidiary of Lupin, a global pharmaceutical player, Nanomi is positioned to leverage additional resources and expertise in the development of complex injectables. The company is committed to innovation and quality, making it a notable participant in the controlled release drug delivery sector.

4. DEC International NZ Limited

• Website: decnz.com
• Ownership type: Private
• Headquarters: Hamilton, Waikato, New Zealand
• Employee distribution: New Zealand 100%
• Founded year: 1986
• Headcount: 51-200
• LinkedIn: dechealthcare

DEC International NZ Limited, based in Hamilton, New Zealand, is a private biotech manufacturer founded in 1986. The company specializes in the development and production of drug delivery devices, particularly focusing on controlled release technologies. They collaborate with biotech firms to provide expertise in the design and manufacturing of devices that ensure effective drug delivery. With over 40 years of experience in hormone-releasing implant development, DEC supports its partners from the clinical phase through to commercialization. Their capabilities include the use of proprietary manufacturing technologies that allow for scalable production of silicone and polymeric devices. DEC has achieved FDA approval and adheres to stringent quality management systems, making them a reliable partner in the biotech and pharmaceutical sectors. Their commitment to innovation and excellence in manufacturing positions them as a significant player in the controlled release drug delivery market.

5. NAL Pharma/IA Capital

• Website: nalpharma.com
• Ownership type: Private
• Headquarters: Hong Kong S.A.R
• Founded year: 2006
• Headcount: 51-200
• LinkedIn: nal-pharma-ia-capital

NAL Pharma, founded in 2006 and based in Hong Kong, is a private biopharmaceutical company dedicated to the development of proprietary drug delivery systems and novel dosage forms. The company collaborates with pharmaceutical firms to enhance drug delivery mechanisms, thereby improving patient compliance across various therapeutic areas, including oncology, pain management, and central nervous system disorders. NAL Pharma's innovative technologies include Bio-CR, which focuses on oral controlled-release systems, and Bio-NN, which utilizes nanoparticle technology for targeted delivery. Their approach not only aims to convert patent-expiring blockbuster drugs into new formulations but also seeks to enhance the safety and efficacy of existing medications. NAL Pharma operates internationally, partnering with major pharmaceutical companies to expedite product development and commercialization in global markets.

6. Nemera

• Website: nemera.net
• Ownership type: Private Equity
• Headquarters: Fontaines-Sur-Saône, Auvergne-Rhône-Alpes, France
• Employee distribution: France 61%, United States (USA) 19%, Brazil 10%, Other 11%
• Latest funding: October 2018
• Founded year: 2015
• Headcount: 1001-5000
• LinkedIn: nemera

Nemera is a medical device manufacturer based in Fontaines-Sur-Saône, France, founded in 2015. The company focuses on drug delivery device solutions and combination product services, partnering with pharmaceutical, biotechnology, and generic industries. Their offerings include device development, clinical manufacturing, and innovation support, aimed at maximizing treatment efficacy and ensuring safe medication delivery. With a workforce of approximately 1,390 employees, Nemera operates primarily in France, the United States, Brazil, Germany, and Poland. Their commitment to patient-centric solutions is evident in their approach to device strategies, which prioritize user needs and regulatory compliance. Nemera's expertise in the field positions them as a significant player in the drug delivery market, particularly in the context of controlled release systems.

7. ProLynx

• Website: prolynxinc.com
• Ownership type: Venture Capital
• Headquarters: San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Seed, $55,000, August 2020
• Founded year: 2009
• Headcount: 1-10
• LinkedIn: prolynx-llc

ProLynx Inc, founded in 2009 and based in San Francisco, California, is a biotechnology firm dedicated to advancing drug delivery systems and drug development. The company specializes in extending the half-life of therapeutic agents through innovative technologies. ProLynx's proprietary drug delivery systems are designed to provide controlled and sustained release of drugs, addressing significant challenges in the pharmaceutical industry. They have developed a unique β-eliminative drug delivery system that allows for predictable drug release over extended periods, which is crucial for improving patient compliance and therapeutic outcomes. ProLynx has engaged in collaborations with various pharmaceutical companies and research institutions, showcasing their commitment to innovation and partnership in the field. The company has also received seed funding, with the last reported amount being $55,244 in August 2020, indicating ongoing support for their research and development efforts.

8. Oakwood Labs

• Website: oakwoodlabs.com
• Ownership type: Private
• Headquarters: Oakwood, Ohio, United States (USA)
• Employee distribution: United States (USA) 98%, Canada 2%
• Founded year: 1997
• Headcount: 51-200
• LinkedIn: oakwood-laboratories

Oakwood Labs, founded in 1997 and based in Oakwood, Ohio, is a pharmaceutical development company that specializes in sustained release injectable products. The company employs its proprietary Chroniject™ technology, which is a polymer microsphere-based system designed for controlled drug delivery. Oakwood Labs provides a full range of services, including feasibility studies, formulation optimization, and GMP aseptic manufacturing. Their expertise extends to various therapeutic areas such as oncology, central nervous system disorders, and endocrinology. With a workforce of around 85 employees, Oakwood Labs has established itself as a reliable partner for pharmaceutical companies looking to develop long-acting injectables. The company operates an FDA-approved facility, ensuring compliance with rigorous quality standards for both clinical and commercial production.

9. Osmopharm SA

• Website: osmopharm.com
• Ownership type: Corporate
• Headquarters: Bedano, Ticino, Switzerland
• Employee distribution: Switzerland 100%
• Latest funding: November 2023
• Founded year: 1994
• Headcount: 11-50
• LinkedIn: osmopharm-sa

Osmopharm SA, founded in 1994 and based in Bedano, Ticino, Switzerland, is a pharmaceutical manufacturer that specializes in modified release oral drug delivery systems. The company has established itself as a significant player in the industry, providing advanced manufacturing services to over 100 pharmaceutical firms worldwide. Their expertise lies in developing formulations that achieve desired therapeutic effects while extending the life cycles of existing products. Osmopharm employs advanced galenic technologies to create various dosage forms, including pellets and ion-exchange resinates. The company operates a facility that spans approximately 6,000 square meters, ensuring they can meet the demands of their global clientele. Their commitment to quality is underscored by their authorization from Swissmedic, the Swiss National Health Authorities, which enforces some of the strictest manufacturing standards in the world.

10. Osmotica Pharmaceutical Corp.

• Website: osmotica.com
• Ownership type: Corporate
• Headquarters: Bridgewater, New Jersey, United States (USA)
• Employee distribution: United States (USA) 93%, Argentina 4%, Spain 2%
• Latest funding: $111.0M, October 2022
• Founded year: 2000
• Headcount: 201-500
• LinkedIn: osmotica-pharmaceutical-corp.

Osmotica Pharmaceutical Corp., founded in 2000 and based in Bridgewater, New Jersey, is a pharmaceutical company that focuses on controlled and modified drug delivery systems. The company is dedicated to developing innovative treatments aimed at addressing unmet medical needs within the healthcare sector. Their operations include conducting clinical trials to evaluate new therapies, ensuring that they meet safety and efficacy standards required for regulatory approval. With a workforce of approximately 134 employees, Osmotica has a significant presence in the United States, with additional operations in Argentina and Spain. The company has recently secured $111 million in funding, which underscores its commitment to advancing its research and development initiatives. Osmotica's customer base includes healthcare providers and patients seeking effective pharmaceutical solutions, highlighting its role in improving patient outcomes through innovative drug delivery methods.

11. Lyndra Therapeutics

• Website: lyndra.com
• Ownership type: Venture Capital
• Headquarters: Watertown, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series E-K, $101.0M, December 2023
• Founded year: 2015
• Headcount: 51-200
• LinkedIn: lyndra

Lyndra Therapeutics, founded in 2015 and based in Watertown, Massachusetts, is a pharmaceutical company dedicated to revolutionizing drug delivery systems. The company specializes in long-acting oral therapies aimed at enhancing medication adherence for patients with chronic health conditions. Their flagship LYNX® drug delivery platform has been formulated with multiple active pharmaceutical ingredients and is being developed for various therapeutic areas, including mental health and cardiometabolic diseases. Lyndra has received significant funding, including a recent $101 million in Series E funding in December 2023, which underscores their commitment to advancing their innovative solutions. Their research includes pivotal studies for oral weekly risperidone, targeting schizophrenia, and other conditions, showcasing their focus on improving patient outcomes through reduced dosing frequency.

12. Medherant Limited

• Website: medherant.co.uk
• Ownership type: Venture Capital
• Headquarters: Coventry, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 100%
• Latest funding: $3.6M, April 2023
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: medherant-limited

Medherant Limited is a clinical-stage pharmaceutical company based in Coventry, England, founded in 2015. The company specializes in transdermal drug delivery systems, utilizing its proprietary TEPI Patch technology. This innovative approach allows for the development of patches that enhance drug delivery for various medical conditions, particularly in women's health. Medherant's lead product is a testosterone patch aimed at addressing hypoactive sexual desire disorder in post-menopausal women. The company collaborates with pharmaceutical partners to formulate drugs for transdermal delivery, enhancing the convenience and effectiveness of treatment. Medherant has received funding from Mercia Fund Management and private investors, which supports its ongoing research and development efforts. Their technology has shown promise in clinical trials, indicating a commitment to improving patient care through advanced drug delivery solutions.

13. GP-Pharm

• Website: gp-pharm.com
• Ownership type: Private
• Headquarters: L'Hospitalet De Llobregat, Catalonia, Spain
• Employee distribution: Spain 53%, Argentina 45%, Uruguay 3%
• Founded year: 2000
• Headcount: 51-200
• LinkedIn: lab.-gp-pharm

GP-Pharm is a private pharmaceutical company based in L'Hospitalet De Llobregat, Catalonia, Spain, founded in 2000. The company specializes in the development and manufacturing of injectable drugs, with a particular focus on oncology, urology, and women's health. GP-Pharm is recognized for its expertise in drug delivery systems, including controlled release technologies such as microespheres, liposomes, and lipid nanoparticles. They offer comprehensive services as a Contract Development and Manufacturing Organization (CDMO), which includes everything from research and development to preclinical and clinical studies, ultimately bringing products to market. The company has established partnerships with various pharmaceutical firms, enhancing its international presence and allowing it to market its products across Europe, the United States, and Latin America. GP-Pharm is committed to continuous innovation and invests in advanced technologies to improve its offerings. Their facilities have been approved by multiple regulatory agencies, ensuring compliance with international standards.

14. Yeshbio Solutions Private Limited

• Website: yeshbio.com
• Ownership type: Private
• Headquarters: Hyderabad, Telangana, India
• Founded year: 2019
• Headcount: 1-10
• LinkedIn: yeshbio-solutions-private-limited

Yeshbio Solutions Private Limited, founded in 2019 and based in Hyderabad, India, is a healthcare company dedicated to creating innovative healthcare solutions and manufacturing biomaterials. The company focuses on developing therapeutic biomaterials and controlled drug delivery systems, catering to both healthcare professionals and patients. Their mission is to enhance patient health through personalized and precision medical care. Yeshbio has established an R&D center in India, where they are working on custom medical devices for controlled drug delivery and habit cessation therapy. They have received recognition as a startup from the Indian government and have been involved in various incubation programs, indicating their active participation in the healthcare innovation space. Their product line includes several formulations aimed at controlled drug release, showcasing their commitment to advancing this field.

15. DelSiTech Ltd

• Website: delsitech.com
• Ownership type: Venture Capital
• Headquarters: Turku, Southwest Finland, Finland
• Employee distribution: Finland 100%
• Latest funding: $10.9M, January 2024
• Founded year: 2001
• Headcount: 11-50
• LinkedIn: delsitech-ltd

DelSiTech Ltd, founded in 2001 and based in Turku, Finland, is a biotechnology firm that specializes in innovative drug delivery technologies. The company is known for its advanced biodegradable silica-based solutions designed for controlled release of drugs. DelSiTech collaborates with various pharmaceutical and biotech partners to develop long-acting injectables and ocular drug delivery systems. Their technology addresses critical challenges in drug delivery, aiming to improve patient compliance and therapeutic outcomes. DelSiTech has a growing pipeline of products targeting unmet clinical needs and has secured significant funding, with a recent amount of over 10 million euros reported in January 2024. This funding supports their ongoing research and development efforts, positioning them as a notable player in the controlled release drug delivery market.

16. Abon Pharmaceuticals, LLC

• Website: abonpharma.com
• Ownership type: Private
• Headquarters: Chestnut Ridge, New York, United States (USA)
• Employee distribution: United States (USA) 89%, United Kingdom (UK) 5%, Portugal 5%
• Founded year: 2009
• Headcount: 11-50
• LinkedIn: abon-pharmaceuticals-llc

Abon Pharmaceuticals, LLC, based in Chestnut Ridge, New York, is a private pharmaceutical company founded in 2009. The firm specializes in the development of complex generics and proprietary products, focusing on drug delivery research and manufacturing. Abon offers a variety of injectable and oral dosage forms, catering to healthcare providers and pharmaceutical companies seeking innovative solutions. The company prides itself on a science-based approach to product development, utilizing modern technology and scientific methods to enhance product quality and patient compliance. Abon has a proven track record in dosage form development, with multiple patents to its name. Their recent FDA approval for a generic version of Carafate® (sucralfate) Oral Suspension highlights their active role in the pharmaceutical industry and their commitment to bringing complex products to market. Abon is also seeking global partners for manufacturing and distribution, indicating a proactive approach to expanding their reach and capabilities in the drug delivery space.

17. Nostrum Laboratories, Inc.

• Website: nostrumpharma.com
• Ownership type: Private
• Headquarters: United Kingdom (UK)
• Employee distribution: United States (USA) 100%
• Founded year: 1995
• Headcount: 11-50
• LinkedIn: nostrum-laboratories-inc.

Nostrum Laboratories, Inc. is a private pharmaceutical company founded in 1995, primarily based in the United States. The company specializes in the development and commercialization of specialty pharmaceutical products, with a strong emphasis on controlled-release formulations. Nostrum's portfolio includes both branded and generic drugs, showcasing their capability in the pharmaceutical market. They are particularly focused on innovative therapies aimed at treating cardiovascular diseases and respiratory disorders. With a robust intellectual property portfolio, Nostrum is dedicated to advancing drug delivery technologies that improve patient outcomes. Their operations extend to facilities in both the United States and India, where they engage in research and development to support their product offerings. The company is committed to creating patient-friendly dosage forms that reduce the frequency of drug administration, thereby enhancing patient compliance, especially among populations requiring complex medication regimens.

18. AustarPharma, LLC

• Website: austarpharma.com
• Ownership type: Private
• Headquarters: Edison, New Jersey, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2004
• Headcount: 11-50
• LinkedIn: austarpharma-llc

AustarPharma, LLC is a pharmaceutical company based in Edison, New Jersey, founded in 2004. The company specializes in drug delivery technologies, particularly focusing on controlled-release systems. With a team of professionals averaging over twenty-five years of experience in the pharmaceutical industry, AustarPharma offers a range of services including cGMP manufacturing and drug development. Their facility in Edison is equipped to handle various drug delivery technologies, including water-insoluble and controlled-release platforms. The company has developed successful collaborations with multiple biotech and pharmaceutical firms, providing comprehensive services from formulation development to commercial manufacturing. AustarPharma's acquisition of an FDA and EU approved cGMP facility in 2009 significantly enhanced their capacity to support clients in navigating the regulatory landscape and bringing new drugs to market. They are also involved in the sales and marketing of generic drug products, showcasing their commitment to improving patient outcomes through innovative drug delivery solutions.

19. Antares Pharma Inc.

• Website: antarespharma.com
• Ownership type: Corporate
• Headquarters: Ewing Township, New Jersey, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $960.0M, April 2022
• Founded year: 1979
• Headcount: 51-200
• LinkedIn: antares-pharma-inc-

Antares Pharma Inc., based in Ewing Township, New Jersey, is a biotechnology company founded in 1979. The company focuses on innovative drug delivery technologies and pharmaceutical products aimed at enhancing patient experiences. Their notable offerings include the ENHANZE® technology, which allows for rapid subcutaneous delivery of drugs, significantly reducing the time required for treatment administration. Antares Pharma also develops auto-injectors and multi-dose pen technologies, showcasing their commitment to improving drug delivery systems. The company has received substantial funding, with a reported amount of $960 million in April 2022, indicating strong investor confidence in their capabilities and future prospects. Antares Pharma collaborates with various pharmaceutical companies and healthcare providers to optimize treatment protocols and improve patient outcomes.

20. Tapemark

• Website: tapemark.com
• Ownership type: Corporate
• Headquarters: West Saint Paul, Minnesota, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: August 2022
• Founded year: 1952
• Headcount: 51-200
• LinkedIn: tapemark

Tapemark, founded in 1952 and based in West Saint Paul, Minnesota, is a pharmaceutical company that specializes in drug delivery systems. The company provides a variety of services, including transdermal patch and oral film drug delivery, as well as formulation and analytical services. Tapemark primarily serves pharmaceutical companies that seek innovative solutions for drug administration. Their proprietary platforms, such as IontoPatch™, MacroPerm™, and MicroDerm™, highlight their commitment to advancing drug delivery technologies. With a workforce of 51-200 employees, Tapemark has established itself as a significant player in the drug delivery industry, focusing on both development and manufacturing processes to meet the needs of their clients.

21. Biograil

• Website: biograil.com
• Ownership type: Venture Capital
• Headquarters: Roskilde, Denmark
• Employee distribution: Denmark 100%
• Latest funding: Seed, October 2022
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: biograil

Biograil, founded in 2019 and based in Roskilde, Denmark, is a pharmaceutical company that specializes in innovative drug delivery systems. The company leverages its proprietary BIONDD™ technology to convert injectable medications into convenient oral capsules. This transformation not only enhances patient compliance but also improves treatment efficacy. Biograil primarily serves pharmaceutical companies and healthcare providers looking for effective solutions for biologic drug delivery. The company is currently in the pre-clinical stage and has established strong strategic partnerships with major players in the pharmaceutical industry. Notably, Biograil has received seed funding to support its research and development efforts, indicating investor confidence in its potential to disrupt the market for injectable pharmaceuticals. Their technology has shown promise in overcoming the usual barriers associated with oral dosing, making it a significant player in the drug delivery sector.

22. Re-Vana Therapeutics

• Website: revanatx.com
• Ownership type: Venture Capital
• Headquarters: Belfast, Northern Ireland, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 100%
• Latest funding: Series A, $12.1M, November 2022
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: re-vana-ltd

Re-Vana Therapeutics is a biotechnology company based in Belfast, Northern Ireland, that focuses on developing advanced ocular drug delivery systems. Founded in 2016, the company aims to improve treatment options for serious eye diseases through innovative sustained-release therapeutics. Their flagship products, EyeLief and OcuLief, utilize proprietary photocrosslinked biodegradable technologies to deliver drugs effectively over extended periods, ranging from six months to two years. This approach addresses the common issues of frequent injections and poor patient compliance associated with traditional ocular treatments. Re-Vana has successfully raised approximately $12 million in funding, demonstrating investor confidence in their technology and market potential. The company collaborates with pharmaceutical partners to explore the feasibility of their drug delivery systems, positioning itself for future growth in the expanding ophthalmic pharmaceutical market.

23. Lifecare Innovations Private Limited

• Website: lifecareinnovations.com
• Ownership type: Private
• Headquarters: New Delhi, Delhi, India
• Employee distribution: India 100%
• Founded year: 2000
• Headcount: 51-200
• LinkedIn: lifecare-innovations-private-limited

Lifecare Innovations Private Limited, founded in 2000 and based in New Delhi, India, is a biotechnology firm that focuses on liposomal technology and controlled release pharmaceuticals. The company is dedicated to developing and manufacturing innovative healthcare products aimed at treating serious fungal infections, particularly in immunocompromised patients. Their notable products include FUNGISOME® Gel and FUNGISOME® i.v., which utilize advanced liposomal formulations to enhance drug delivery and efficacy. Lifecare Innovations is actively engaged in research and development, employing novel drug delivery systems to improve patient outcomes. The company has received multiple awards for its contributions to biotechnology and has established itself as a pioneer in the field of liposomal pharmaceuticals, particularly in the context of addressing critical health challenges such as mucormycosis. Their commitment to innovation and quality positions them as a significant player in the controlled release drug delivery market.

Controlled Release Drug Delivery Insights: Key Companies

Want to Find More Controlled Release Drug Delivery Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!